coin-img-BTCBTC-3.02%coin-img-SOLSOL-1.69%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.26%coin-img-UBOXUBOX-26.77%coin-img-HYPEHYPE-2.51%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.70%coin-img-BTCBTC-3.02%coin-img-SOLSOL-1.69%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.26%coin-img-UBOXUBOX-26.77%coin-img-HYPEHYPE-2.51%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.70%coin-img-BTCBTC-3.02%coin-img-SOLSOL-1.69%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.26%coin-img-UBOXUBOX-26.77%coin-img-HYPEHYPE-2.51%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.70%coin-img-BTCBTC-3.02%coin-img-SOLSOL-1.69%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.26%coin-img-UBOXUBOX-26.77%coin-img-HYPEHYPE-2.51%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.70%
user-avatar
CNBC TV18

Glenmark Q1 net profit jumps 930% to ₹483 crore as India and North America drive growth

AI Market Summary
Glenmark Pharmaceuticals reported a sharp YoY jump in Q1 consolidated profit and strong revenue and EBITDA growth, led by India formulations and North America, alongside multiple US launches and a growing respiratory pipeline. The results and guidance on approvals underscore operational momentum and improved margins, supporting risk appetite in the specific issuer, but the news is unlikely to be market-moving for broader macro assets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-1.58%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Glenmark Pharmaceuticals Ltd reported a 930% year-on-year surge in consolidated net profit to ₹483 crore for the first quarter of FY2025. Revenue rose 23% to ₹4,018 crore, while EBITDA climbed 39% to ₹805 crore and the EBITDA margin improved to 20%. The company said India and North America were the main growth drivers. The stock closed up 2.17% on the BSE.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.